We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take ...

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

HIMS posted stellar Q1 FY 2025; growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Click here to ...

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

Nevertheless, European companies have found themselves in the sights of America’s president, who is irked by the fact that ...

Telemonitoring with continuous glucose monitoring and insulin pens outperforms standard-of-care practices for improving ...

In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

The agreement unites two brands that are popular with Gen Z and helps the buyer diversify its supply chain outside of China. Pipeline operator Williams will seek to build two natural-gas supply lines ...

Thammasat University Hospital, in collaboration with Novo Nordisk Pharma (Thailand) Ltd. ('Novo Nordisk'), announced a collaboration titled 'Partnership Project for the Transition into the Fourth ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...